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Targets of Egr1 <p>UV stimulation of prostate cells causes an apoptotic response that is dependent on the zinc finger transcription factor Egr1; down- stream targets of Egr1 in this response were identified.</p>
Abstract
Background:  UV irradiation activates the epidermal growth factor receptor, induces Egr1
expression and promotes apoptosis in a variety of cell types. We examined the hypothesis that Egr1
regulates genes that mediate this process by use of a chip-on-chip protocol in human tumorigenic
prostate M12 cells.
Results:  UV irradiation led to significant binding of 288 gene promoters by Egr1. A major
functional subgroup consisted of apoptosis related genes. The largest subgroup of 24 genes belongs
to the epidermal growth factor receptor-signal transduction pathway. Egr1 promoter binding had
a significant impact on gene expression of target genes. Conventional chromatin
immunoprecipitation and quantitative real time PCR were used to validate promoter binding and
expression changes. Small interfering RNA experiments were used to demonstrate the specific role
of Egr1 in gene regulation. UV stimulation promotes growth arrest and apoptosis of M12 cells and
our data clearly show that a downstream target of the epidermal growth factor receptor, namely
Egr1, mediates this apoptotic response. Our study also identified numerous previously unknown
targets of Egr1. These include FasL, MAX and RRAS2, which may play a role in the apoptotic
response/growth arrest.
Conclusions: Our results indicate that M12 cells undergo Egr1-dependent apoptotic response
upon UV stimulation and led to the identification of downstream targets of Egr1, which mediate
epidermal growth factor receptor function.
Background
Early growth response-1 (Egr1) is a zinc-finger nuclear phos-
phoprotein and transcription factor [1,2]. The gene for Egr1
(also known as Zif/268, NGFI-A and Knox24) encodes a 533
amino acid protein with 6 Cys2-His2 zinc finger motifs that
exhibit partial homology to the gene sequence encoding the
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DNA binding domain of the Wilms tumor-1 suppressor (WT1)
[3]. Indeed, both Egr1 and WT1 bind the Egr1 consensus reg-
ulatory sequence CGCCCCCGC in a zinc-dependent manner.
Egr1 was first cloned as NGFI-A [4] from NGF-induced PC12
cells, and as Egr1 from mouse cells [1]. Early studies indicated
its potential roles in cardiac and neural differentiation in a
pluripotent EC (endothelial cells) line [1] and a role in mono-
cytic differentiation of myeloid leukemia cells [5]. Subsequent
studies have identified roles of Egr1 in cell growth, differenti-
ation, inflammation associated with atherosclerosis [6], car-
diac and pulmonary fibrosis [7,8] and a variety of roles in the
physiology of the central nervous system.
In several types of human tumor cells, Egr1 exhibits suppres-
sor gene activity via the binding to and transactivation of
major tumor suppressor factors, including transforming
growth factor-β1, p53, p73, and PTEN, indicating that Egr1 is
a tumor suppressor factor (reviewed in [2]). Suppression of
Egr1 expression is common in non-small cell lung cancers [9]
and glioblastomas [10]. Egr1 is commonly deleted in the mye-
lodysplastic syndrome (the acute myelogenous leukemia pre-
cursor condition), in mouse mutagenesis studies it induced
myelodysplastic syndrome leukemogenesis, and acute myel-
ogenous leukemia in mice was strongly associated with hap-
loinsufficiency of Egr1 [11]. It has been proposed that Egr1
participates in, or coordinates a network of, tumor suppressor
activities that serve to preserve contact inhibition of normal
cells and promote anoikis of transformed variants [2].
In contrast, accumulating evidence based on in vitro studies,
a survey of human surgical specimens, and transgenic mouse
models indicate that Egr1 plays an important role in progres-
sion of prostate cancer [12]. Antisense Egr1 treatment of
mouse prostate cell lines suppresses expression of Egr1 and
several manifestations of transformation [13]. It has been
suggested that Egr1 directly regulates genes that play a role in
the development of prostate cancer [2,14]. A potential role of
intracellular trafficking and posttranslational modification
has also been implicated [15].
The expression of Egr1 is regulated in part through six CArG
boxes located in the proximal 3' untranslated region of the
Egr1 promoter [16]. CArG boxes, also known as serum
response elements, have a consensus sequence CC(AT)6GG
and bind phosphorylated serum response factor. The serum
response factor is a major effector of the Map kinase/ERK
pathway, mediator of a variety of growth factor receptors such
as the epidermal growth factor receptor (EGFR) [17]. Activa-
tion of the EGFR leads to rapid expression of Egr1 in a variety
of settings [18], including prostate cancer cells [19].
EGFR is strongly activated by a broad spectrum of irradiation
[20]. The mechanism may involve the generation of reactive
oxygen species [21] and may require the aggregation and
internalization of EGFR [22]. Ultraviolet (UV) activation of
EGFR is accompanied by the formation of complexes between
activated EGFR and SOS (Son of sevenless), Grb2, phosphol-
ipase-Cγ (PLCγ) and SHC (Src homologous and collagen) [21].
Downstream signaling leads to rapid and transient activation
of Egr1 expression. Activation is inhibited by suramin, sug-
gesting that autocrine factors may mediate activation of the
EGFR. UV stimulation later results in apoptosis. Here we
examined human prostate M12 cells, a tumorigenic line
derived from SV-40 immortalized P69 cells by serial passage
in mice [23]. In these cells Egr1 is rapidly induced by treat-
ment with UV radiation and serves as a model of Egr1 func-
tion. Our goal is to show that genes are bound by Egr1 in living
cells upon UV stimulation, which provides a profile of genes
more relevant to the mechanism of the EGFR pathway than
expression analysis alone. We used a 'ChIP-on-chip' protocol
and identified 288 promoters that were significantly bound
by Egr1, which commonly functioned to regulate transcrip-
tion. A large functionally related group of 24 genes is associ-
ated with the EGFR pathway and includes numerous
mediators of apoptosis. Also, our results show several new
targets of Egr1 (including MAX and RRAS2) that have previ-
ously not been associated with it. Indeed, UV treatment leads
to inhibition of growth and apoptosis in an Egr1-dependent
manner. The results illustrate that Egr1-regulated genes are
required for the apoptotic response of UV treated prostate
cancer cells.
Results
UV irradiation of M12 cells induces expression of 
endogenous Egr1 RNA and protein expression via the 
ERK1/2 pathway
Egr1 is barely detected in resting cells whereas irradiation
with UV-C rapidly leads to markedly increased Egr1 expres-
sion. Dose-response and time-course experiments identified
40 J/m2 as the optimal dose for Egr1 over-expression of
mRNA and protein. Gene expression was increased approxi-
mately 3-fold at 30 minutes after treatment as measured by
quantitative real time PCR (qRT-PCR; Figure 1a). Maximum
protein expression was observed 2 h after UV irradiation (40
J/m2; Figure 1b). M12 cells are metastatic prostate cancer
cells and we observed high basal expression of Egr1 in these
cells compared to several other prostate cancer cell lines. We
chose these cells, therefore, as our goal was to immunoprecip-
itate Egr1 from UV-treated cells and to use untreated cells as
a true control for DNA immunoprecipitated from the UV-
treated cells. We have shown earlier that stress stimuli, such
as DNA-damaging agents that induce Egr1 expression, prefer-
entially activate the stress activated Jun kinase pathway
(JNK) and, to a lesser extent, the ERK1/2 pathway, while the
p38 MAP kinase pathway is minimally affected in a variety of
cell types [21,24]. To test whether ERK1/2 also may be
involved in Egr1 expression following irradiation, M12 cells
were treated with an ERK1/2 inhibitor, U0126, 45 minutes
prior to UV stimulation. Egr1 expression remained at control
levels in UV irradiated cells after treatment with U0126,
whereas the cells that were treated with UV-C alone exhibitedhttp://genomebiology.com/2008/9/11/R166 Genome Biology 2008,     Volume 9, Issue 11, Article R166       Arora et al. R166.3
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the characteristic induction of Egr1 protein, indicating that
ERK1/2 acted upstream of Egr1 expression (Figure 1c). These
results indicate that ERK1/2 is likely the dominant upstream
MAP kinase pathway of induction of endogenous Egr1 protein
expression in M12 cells.
Chromatin immunoprecipitation revealed the 
formation of in vivo bound Egr1 DNA complexes
To determine whether endogenous Egr1 protein of UV-stim-
ulated cells was effectively translocated to the nucleus and
bound DNA, we examined whether UV stimulation increased
the binding of Egr1 to chromatin. Formaldehyde-crosslinked
DNA was isolated from equal numbers of UV-stimulated and
mock-stimulated cells, sonicated, and precipitated with anti-
Egr1 (sc 110) antibody. Western analysis of anti-Egr1-precip-
itated DNA revealed Egr1, while Egr1 was barely detected in
chromatin from control cells or chromatin pulled down with
nonspecific IgG (Figure 2a). In addition, more DNA was
recovered following UV irradiation compared to mock-
treated cells. No detectable DNA was recovered from UV-
treated cells when non-immune rabbit IgG control serum was
used for chromatin immunoprecipitation (ChIP; Figure 2b).
These results indicate that UV irradiation led to a large and
specific increase in chromatin-bound Egr1.
Identification of Egr1-bound promoters by promoter 
array hybridization
To identify the promoters bound by Egr1, we utilized pro-
moter arrays containing approximately 12,000 promoter
sequences amplified from normal human genomic DNA in
the region of 500 nucleotides 3' of a known transcription start
site to 1,000 nucleotides 5' of the transcription start site. This
is the region of genes that contains many known functional
transcriptional regulatory motifs, and is often the most CpG
rich and G+C rich region in a gene [25]. Thus, this region is
the most likely to harbor the CpG and G+C-rich consensus
Egr1 binding site (EBS; 5' GCGGGGGCG 3'). A search for this
motif in approximately 17,000 human genes with available
Egr1 induction upon UV-C stimulation Figure 1
Egr1 induction upon UV-C stimulation. (a) Time course and dose response of Egr1 induction upon UV-C stimulation was measured by qRT-PCR. RNA 
was collected at various time points and at different doses of UV-C in order to determine the optimal dose (40 J/m2) and time point (2 h) for Egr1 
expression. The upper panel shows the time course and the lower panel shows the dose response of Egr1 expression upon UV-C stimulation. (b) 
Western analysis using anti-Egr1 to define time of maximum UV response. (c) Western analysis of M12 cells treated with UV-C or not (control) in the 
presence and absence of ERK1/2 inhibitor (ErkI). The results show that prior treatment with ErkI resulted in negligible induction of Egr1 upon UV 
stimulation. Hence, at least 90% of Egr1 induction in these cells was downstream of the ERK MAP kinase.http://genomebiology.com/2008/9/11/R166 Genome Biology 2008,     Volume 9, Issue 11, Article R166       Arora et al. R166.4
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annotation of transcription start sites in Refseq (NCBI refer-
ence sequences) revealed two major areas of Egr1 consensus
binding motifs (Figure 2c). These regions were located at
about -50 nucleotides 5' and about +100 nucleotides 3' of the
transcription start site.
The ChIP-captured DNA from the UV-irradiated and non-
irradiated cells were amplified in the presence of Cy3- or Cy5-
conjugated nucleotide analogues, mixed in equal amounts
and applied to the arrays. An M-A scatter plot of the com-
bined data is shown in Figure 2d. The plot reveals a large pop-
ulation of increased array intensities (outliers) in the
quadrant of positive M values and A > 11, indicating that UV
stimulation preferentially leads to increased promoter bind-
ing by Egr1 in comparison to control DNA. Since the arrays
are printed in triplicate, the experiment yields 12 array inten-
sity measurements for each promoter. The fold changes are
likely underestimates of the true change because the presence
of any contaminating total genomic DNA in the ChIP samples
reduces the dynamic range of the experiment. The signifi-
cance (volcano) plots [26], which incorporate the B-values,
confirm the existence of preferentially increased binding of
DNA from UV-stimulated cells (Figure 2d). Array intensities
judged as significantly increased were selected by two crite-
ria: p < 0.005, and fold change >1.4. At least half of the genes
also had a positive B value. The double criteria identified 288
gene promoters (5 were not considered further as they were
cDNA clones with no sequence availability), which are listed
in Table S1 in Additional data file 2. All the data files have
been submitted to [GEO:GSE10585].
ChIP-on-chip hybridization results Figure 2
ChIP-on-chip hybridization results. (a) Western analysis of ChIP products for M12 cells treated with UV-C or not (control). (b) Yield and size of DNA 
precipitated with anti-Egr1 from M12 cells following treatment with UV-C. (c) Distribution of the consensus Egr1-binding sequence (5' GCGGGGGCG 3') 
in approximately 17,000 human genes. (d) M-A plots of promoter array hybridization intensities of ChIP products from control M12 cells and cells treated 
with 40 J/m2 UV-C for 2 h. The lower panel shows significance (volcano) plots of the hybridization intensity data for ChIP products of M12 cells treated 
with UV-C for 2 h compared with control non-treated ChIP sample. The right arm of the lower plot shows significantly bound promoters.http://genomebiology.com/2008/9/11/R166 Genome Biology 2008,     Volume 9, Issue 11, Article R166       Arora et al. R166.5
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Confirmation of the differential expression of UV-
induced genes using bioinformatics criteria
Several observations indicate that the significant changes
observed here accurately reflect differential precipitation and
array binding. First, for the 283 genes that exhibited signifi-
cantly altered hybridization following UV irradiation, 112/
283 (39.6%) have perfect Egr1 consensus sites in their pro-
moter sequences. Another 53 genes have probable EBSs
(58.3% in total) whereas the frequency of EBSs in a set of 200
random sequences was only 23% (p < 0.005). Thus, the pro-
moters reported as bound by Egr1 indeed contain a signifi-
cant increase in the frequency of EBSs. Secondly, at least 43/
283 (15%) genes are known to be UV responsive from other
studies (Table S1 in Additional data file 2). A third indication
comes from the identification of 24/283 significantly bound
genes as EGFR-associated genes. These genes were identified
by Pathway studio 5.0 (Ariadne Inc.; see Materials and meth-
ods), which compiles citations indicating that expression of
these genes is associated with EGFR activity and/or expres-
sion. To evaluate this frequency, a set of 1,000 genes was
examined in Pathway studio 5.0 using the same query, which
yielded only 26 genes related to EGFR (p < 0.0001; Table S1
in Additional data file 2 and Figure S1 in Additional data file
4).
We examined the functional nature of the identified genes
using program-assisted literature surveys such as Ariadne
and Ingenuity (Materials and methods). Several functional
groups of genes were apparent. These include regulators of
apoptosis such as Bcl G, BLK, CASP7, BBC3 and also TNFSF5,
TNFSF6 (FasL) and TNFSF19L, which belong to the tumor
necrosis factor (TNF) family. Genes encoding the DNA repair
enzymes NT5E, NME1 and NME2, cytokines, such as IL1R1,
IL15 and IL18R1, the cell cycle regulators CDK8, CDKN1b/
p27, PAK6 and SKP1a and the transcription regulators Ets2,
Egr2, POU4F1, SOX11, EN1 and HSF4 were all among those
containing significantly detected promoters. Genes such as
BBC3, PTPN13, MAX, MAP3K7 and MAP2K1 (MEK1) and 38
others, have been previously documented as UV-responsive
genes (Table S1 in Additional data file 2).
Experimental validation of hybridization intensities
Conventional ChIP was performed to confirm the results of
'ChIP-on-chip' experiments using a set of 25 representative
genes. Primers were designed around the putative EBS on the
target promoters and these were used for qRT-PCR amplifica-
tion of the corresponding sequences from the ChIP-captured
chromatin. The qRT-PCR results show that in 23/25 genes
(92%), UV treatment led to increased PCR yields of 1.4- to 8-
fold compared to control cells (Figure 3a). In contrast, little or
no DNA enrichment was observed for all 25 primer sets when
applied to precipitates prepared using control IgG serum. An
additional five sets of primers for genes that were not on the
'significantly detected promoter' list and did not contain any
EBS showed no DNA enrichment in the UV-stimulated sam-
ples. These observations indicate that the array intensities
reliably reflect increased Egr1-DNA complex formation.
Egr1 promoter binding regulates transcription
To determine whether Egr1 gene binding had an impact on
transcription, Affymetrix gene expression analysis was car-
ried out using U133plus2 arrays with approximately 54,000
probe sets. The analysis was performed on duplicate samples
from M12 control and UV-irradiated cells. There were 2754
genes that showed significantly increased or decreased
expression (2,754/54,675; 5%) as determined by the Affyme-
trix criteria (GCOS v.1.4). All the data files have been submit-
ted to [GEO:GSE10585]. In order to determine whether the
genes bound by Egr1 exhibit increased regulation and, there-
fore, potential phenotypic effects, we compared the average
frequency of significant RNA changes of 5% with that
observed for the 283 differentially bound promoters. This
comparison revealed that twice as many genes (32/283, or
11.3%; Table S2 in Additional data file 3) exhibited significant
changes in mRNA levels. The increased differential expres-
sion among the 283 Egr1 bound genes was significant (p <
0.001). Since numerous other non-Egr1 promoter-binding
events potentially influence changes in transcription upon
UV irradiation, only binding events that dominate regulation
will be reflected in this analysis. It should be noted that bind-
ing events not associated with significant transcriptional
change, either increased or decreased, do not provide evi-
dence of false discovery of binding promoters nor evidence
that Egr1 binding has no impact on transcription, but rather
that the binding does not lead to a dominance over all other
influences.
Thus, the result likely represents a minimum estimate of the
regulatory influence of Egr1 binding. The result is further
supported by comparison of the Affymetrix and qRT-PCR
results. qRT-PCR was carried out on RNA for 37 genes chosen
randomly from the 283 gene set. Of the 37 genes tested, 11
showed over-expression in UV-treated cells, while 21 had
lower expression compared to the control cells (Table 1). Five
genes did not show changes in gene expression. Genes with
fold change values >1.5 were considered over-expressed,
while ones that showed fold change values <0.5 in UV-treated
cells compared to control cells were considered down-regu-
lated. The levels of Egr2 were also verified at the protein level
and there was concordance between the RNA and the protein
levels demonstrating up-regulation of Egr2 (Figure 3b). Com-
parison of qRT-PCR with the Affymetrix data is limited as
only 6 of these 37 chosen genes (16.2%) were among the sig-
nificantly differentially expressed genes by the Affymetrix cri-
t e r i a .  H o w e v e r ,  a l l  v a l u e s  a g r e e d  i n  s i g n  w i t h  a n  o v e r a l l
Pearson correlation coefficient of 0.784 (p = 0.06), indicating
qualitative agreement between the Affymetrix intensity val-
ues and the qRT-PCR-measured expression changes. In a
converse test, we compared the intensity values of all the 32
of the genes with significant Affymetrix expression changes to
the corresponding M-values observed with the promoterhttp://genomebiology.com/2008/9/11/R166 Genome Biology 2008,     Volume 9, Issue 11, Article R166       Arora et al. R166.6
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arrays (Figure S2 in Additional data file 4). The genes exhib-
iting positive expression changes formed a well-resolved pop-
ulation characterized by a Pearson correlation coefficient of
0.68 (p = 0.001; Figure S2 in Additional data file 4).
In order to experimentally test whether significant gene bind-
ing by Egr1 was associated with expression changes that were
Egr1-dependent in vivo, small interfering RNA (siRNA) to
Egr1 (SiEgr1) was used to 'knock down' Egr1 expression in
M12 cells (Figure 3c, lane 4). Transcript levels of 14 represent-
ative genes and Egr1 were measured by qRT-PCR in UV-stim-
ulated M12 cells with or without prior silencing of Egr1. Two
genes (PSD3  and Egr2) that exhibited positive expression
changes and seven genes (EGFR,  RRAS2,  PAK6,  ELF2,
DYRK2, MAX and CASP7) that exhibited decreased mRNA
expression upon UV stimulation were reversed in expression
upon Egr1 silencing (Figure 3d), and one gene, BLK, was fur-
ther repressed upon Egr1 silencing. Four genes (IL11RA,
H3A,  IGFBP6  and  SCAP2) showed no change. Thus, the
expression of at least 10/14 target genes (Figure 3d) was Egr1-
dependent. These observations provide strong experimental
support for the conclusion that UV-induced Egr1 promoter
binding is associated with regulation of transcription. In sum-
mary, of the 25 genes that were validated by conventional
ChIP, 18 were also validated as functional by the effects on
gene expression using qRT-PCR analysis (hence, 18/37 genes
that were shown to have significant transcript level changes
were also shown to have Egr1 bound to their promoters). The
14 genes on which the siRNA experiment was performed were
all from the 37 genes that were validated by qRT-PCR analysis
and this set was chosen as its members exhibited increased
expression and define excellent targets for siRNA testing. The
siRNA results support the conclusion that Egr1 is specifically
bound to and regulates expression of these genes.
Validation of ChIP-on-chip results Figure 3
Validation of ChIP-on-chip results. (a) ChIP products for M12 cells treated with UV-C or untreated controls (control) were analyzed by qRT-PCR. The 
data are expressed as relative fold change of real-time PCR results to untreated control ChIP sample. The experiments were performed in triplicates and 
the error bars represent the triplicate data. (b) Western blot analysis of Egr2 (an Egr1 target gene) to define time of maximum induction. (c) M12 cells 
were treated with siRNA against Egr1 (SiEgr1) or SiGenome control (SiControl) for 48 h followed by UV-C irradiation and western blot confirmed the 
suppression of Egr1 in SiEgr1 treated cells. (d) qRT-PCR analysis of Egr1 target genes using RNA extracted from SiEgr1- or SiGenome control-treated 
M12 cells with or without UV-C irradiation. All the results are expressed relative to GAPDH.http://genomebiology.com/2008/9/11/R166 Genome Biology 2008,     Volume 9, Issue 11, Article R166       Arora et al. R166.7
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UV-C stimulation increases phosphorylation of EGFR 
and inhibitors of EGFR block Egr1 expression
We have previously shown in other cells that UV irradiation
leads to rapid activation of EGFR, activation of the ERK path-
way, and to a large induction of Egr1 expression [21]. Simi-
larly, in M12 cells we observed that ERK1/2 inhibitors block
UV induction of Egr1 (Figure 1c). Phosphorylated EGFR was
greatly increased 30-120 minutes after UV irradiation, as
demonstrated by immunoprecipitation using EGFR antibody
followed by western analysis using an anti-p-tyrosine anti-
body (Figure 4a).
Egr1 expression observed here is downstream of the activated
phosphorylated EGFR in UV-stimulated M12 cells, as shown
by the treatment of cells with PD153035 prior to UV-C irradi-
ation. In addition, since UV irradiation commonly stimulates
autocrine activation of EGFR by liberation of heparin-binding
growth factors [27], we also pretreated the cells with suramin.
Treatment with PD153035 inhibited Egr1 expression by
approximately 85% and suramin inhibited Egr1 expression by
approximately 80% (2 h; Figure 4b). In addition, our 'ChIP-
on-chip' results showed that EGFR expression was sup-
pressed by Egr1 upon UV irradiation (Table 1) and increased
by threefold when the cells were irradiated after silencing
Egr1 expression. The result indicates that Egr1 promoter
binding is specifically associated with decreased transcription
of EGFR, suggesting the presence of a negative feedback loop
controlling EGFR expression by Egr1.
Egr1 over-expression after UV irradiation leads to 
growth inhibition and apoptosis
UV stimulation promotes apoptosis in a variety of cell types.
We therefore examined the growth and survival properties of
Table 1
Gene expression analysis of Egr1 target genes using qRT-PCR of 
RNA extracted at various time points after UV-C treatment of 
M12 cells
Fold change relative to control
30 minutes 1 h 2 h 4 h 6 h
Egr2 2.4 6.9 2.33 1.21 2.43
PSD3 17.2 25.3 9.40 4.86 1.05
TOM22 1.1 1.92 0.95 1.70 1.49
H3A 0.9 1.76 1.07 1.28 0.95
BBC3 1.6 0.71 0.23 0.29 2.28
PTPRO 1.1 0.20 0.44 0.31 20.47
AKAP9 1.4 1.26 1.59 0.66 1.00
TNFSF6 4.6 0.70 1.58 0.62 0.62
CysLTR1 2.07 2.28 3.39 0.66 2.81
HK1 1.43 1.28 1.72 0.91 1.10
NME2 0.82 1.35 2.05 1.53 1.13
NME1 1.06 1.21 1.15 1.08 1.29
IFITM2 0.70 0.88 0.66 0.95 0.77
IL11RA 0.78 0.98 0.77 0.86 0.80
ABCC3 0.79 1.06 0.71 0.70 0.81
SLP1 0.80 0.78 1.01 0.64 0.62
CITED4 0.44 0.62 0.52 0.39 0.24
EGFR 0.22 0.53 0.30 0.30 0.18
CDK8 0.73 1.13 0.62 0.42 0.23
HNRPDP 0.67 0.74 0.20 0.10 0.10
GMPS1 0.86 0.60 0.92 0.41 0.35
GSTA3 0.77 0.44 0.79 0.52 0.53
MAP4 0.49 0.59 0.54 0.73 0.41
MAP2 0.28 0.57 0.44 0.46 0.57
HNRPDP 0.67 1.04 0.20 0.10 0.10
GSTA3 0.77 0.44 0.79 0.52 0.53
FosL2 0.37 0.46 0.50 0.13 0.24
BLK 0.73 0.98 0.37 0.87 0.65
RRAS2 0.63 0.95 0.62 0.57 0.32
PAK6 0.78 0.91 0.69 0.42 0.30
CASP7 0.66 0.81 0.54 0.56 0.23
ELF2 0.54 0.61 0.36 0.19 0.16
BMP4 0.53 0.84 0.42 0.24 0.14
DYRK2 0.36 0.50 0.05 0.10 0.10
MAX 0.64 0.72 0.49 0.27 0.24
PTPN13 0.48 0.73 0.42 0.47 0.22
ETS2 0.67 0.70 0.50 0.49 1.09
EGFR activation upon UV stimulation Figure 4
EGFR activation upon UV stimulation. (a) After 40 J/m2 UV-C radiation, 
100 μg of the protein lysate was used for immunoprecipitation with EGFR 
antibody and this sample was used for immublotting with pTyr antibody 
showing activated EGFR. pEGFR, phosphorylated EGFR. (b) Western blot 
analysis of M12 cells treated with suramin or PD153035 for 45 minutes 
followed by UV-C irradiation.http://genomebiology.com/2008/9/11/R166 Genome Biology 2008,     Volume 9, Issue 11, Article R166       Arora et al. R166.8
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M12 cells following UV stimulation by direct proliferation
measurements over 3 days. Untreated M12 cells in standard
medium grew rapidly to high density whereas cells treated by
UV irradiation were drastically retarded in growth, which was
apparent within 24 h (Figure 5a). By 24 h numerous detached
and floating cells and extracellular debris were apparent, sug-
gesting apoptosis in these cells. A Poly(ADP)-ribose polymer-
ase (PARP) assay revealed a high proportion of PARP
degradation, indicating apoptosis, whereas no degradation
was apparent in untreated cells (Figure 5b). Cell numbers
were reduced 25-fold compared to control cells at 72 h after
treatment. These results indicate that EGFR activation leads
to apoptosis in M12 prostate cells.
To test whether apoptosis of M12 cells was Egr1 dependent in
vivo, M12 cells were treated with siEgr1 to silence Egr1
expression for 48 h followed by UV-C. Egr1 mRNA and pro-
tein expression was effectively silenced by this treatment
(Figure 3c). Cells were collected 24 h later and the PARP assay
demonstrated that cells underwent reduced apoptosis in the
absence of Egr1, clearly showing that Egr1 is an important
mediator of UV-C-induced apoptosis (Figure 5c). These
results confirm the role of Egr1 as a mediator of the apoptosis
response.
Discussion
Egr1 binds a large spectrum of promoters that result in 
transcriptional regulation
We examined the role of Egr1 in UV-irradiated tumorigenic
human M12 prostate cancer cells. Our data show that Egr1
binds to a surprisingly large number of promoters (283 pro-
moters) of an array containing approximately 10,012 unique
proximal promoter sequences. Several of our observations
suggest that Egr1 promoter binding contributes to the regula-
tion of gene expression in UV-treated cells. First, 5.2% (15/
288) of the significantly bound genes are known to interact
with Egr1 and most of them (11 genes) are known to be regu-
lated by Egr1 (Figure S3 in Additional data file 4). For exam-
ple, DMRT1 and EGFR are both shown to be direct targets of
Egr1 and Egr1 binds to their promoters. Second, a majority of
the 283 promoter sequences contain consensus EBSs
(58.3%). Twenty-five genes were examined by conventional
ChIP and the results support the conclusion that ChIP-on-
chip can be used to identify targets and with low false discov-
ery rates. Gene expression studies by qRT-PCR and Affyme-
trix expression analysis show that promoter binding leads to
significant gene expression changes of the target genes. The
qRT-PCR experiments were also done in the very widely used
DU145 prostate cancer cell line, which also over-expresses
Egr1 upon UV irradiation (Table S3 in Additional data file 3).
The results comparing the two cell lines clearly show that the
gene expression pattern of most of the target genes remained
the same across the two cell lines, thus showing that most of
the gene expression changes in the target genes were identi-
cal. Prior treatment with siRNA to silence Egr1 expression in
vivo reversed the expression of Egr1 target genes, clearly sup-
porting the role of Egr1 as a functional transcription factor in
M12 prostate cancer cells. These results are consistent with
the conclusion that promoter arrays have accurately revealed
the identity of 288 genes that are significantly bound by Egr1
upon UV irradiation. The results further suggest that at least
40% of the bound promoters involve DNA binding sequences
that have not been recognized previously.
Egr1 expression is downstream of the EGFR signaling 
pathway and negatively regulates EGFR
We and others have shown that a major mechanism leading
to the expression of Egr1 is via activation of EGFR and the
ERK1/2 pathway [28]. We show that the same mechanism
applies to human prostate M12 cells following UV irradiation,
where Egr1 expression was blocked by inhibitors of EGFR,
ERK1/2 and suramin. This indicates that heparin-binding
EGF-like ligands may be released from the irradiated cells
and participate in the activation of EGFR, consistent with
previous observations from normal mouse cells [21] and
immortalized human keratinocytes [29]. Our study also dem-
onstrates that EGFR itself is a target of Egr1, which leads to
suppression of its transcription and decreased protein
expression. We show that EGFR activated by UV stimulation
induces Egr1, which serves to limit the production of EGFR
and thereby blocks its continued activation and signaling.
Interestingly, the MAX gene was also identified as a target of
Egr1 and its expression was repressed in UV-irradiated cells.
Perini et al. [30] showed that the MAX protein dimerizes with
n-myc and this heterodimer binds to the EGFR promoter and
affects its transcription. Our results clearly demonstrate that
after UV irradiation, Egr1 is significantly bound to the pro-
moters of both EGFR and MAX and the gene expression for
both is suppressed, thus supporting the concerted action of
the two genes [30]. Another indication of this concerted
action comes from the observation that MMP9 mediates
EGFR transactivation by G-protein-coupled receptors and, in
our dataset, MMP9 is also down-regulated [31]. Therefore,
ChIP-on-chip clearly identifies several genes that are
reported to work concordantly to serve a similar function.
Also in the present study, our results show that Egr1 is a tran-
scriptional repressor for a number of its target genes. Egr1 has
predominantly been discussed as a transcriptional activator
by most groups, including ours, but this is the first compre-
hensive study of the identification of Egr1 target genes on a
high throughput scale. These results clearly indicate that Egr1
can act as both a transcriptional activator as well as a repres-
sor protein.
Egr1 mediates UV- induced apoptosis
The most notable physiological change observed in response
to UV irradiation of M12 cells is apoptosis. Egr1 promotes
apoptosis in UV-C-irradiated mouse NIH3T3 cells or mouse
HC11 epithelial cells [21,32]. Similar to previous findings, we
observed apoptosis in M12 prostate cancer cells in response to
UV irradiation. Here we observed that Egr1 over-expressionhttp://genomebiology.com/2008/9/11/R166 Genome Biology 2008,     Volume 9, Issue 11, Article R166       Arora et al. R166.9
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Role of Egr1 in apoptosis Figure 5
Role of Egr1 in apoptosis. (a) Growth curve of M12 cells over a period of 72 h, with or without UV-C irradiation. The experiments were performed in 
triplicates and the error bars represent the data from the triplicate experiments (b) Western blot analysis of M12 cells treated with UV-C, and collected 
at varying time points after UV irradiation. Anti-PARP (to demonstrate apoptosis) was used to identify PARP cleavage product (this antibody only detects 
the cleaved product and not the native protein). (c) M12 cells were treated with SiGenome control and SiEgr1 and followed by UV-C stimulation. Cells 
were collected after 24 h of UV treatment, and western blot analysis, using anti-PARP, showed that Egr1 is involved in apoptosis of M12 cells.http://genomebiology.com/2008/9/11/R166 Genome Biology 2008,     Volume 9, Issue 11, Article R166       Arora et al. R166.10
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mediates UV-induced apoptosis and this response is blocked
by silencing Egr1 expression using siRNA. Several of the Egr1
target genes identified by ChIP-on-chip have a previously
demonstrated role in apoptosis. These include TNFSF6/
CD95L (FasL), FAP1 and fosL2. FasL is pro-apoptotic and is
significantly up-regulated after UV irradiation in our cells and
FAP1/PTPN13, which prevents apoptosis, is significantly
down-regulated in our cell system, thus showing that the Egr1
function in apoptosis occurs through its downstream targets.
Other apoptosis related genes that were bound by Egr1
include Bcl G, BLK, BMF, CASP7, TNFRSF19L, and TNFSF5.
Most are mediators of the classic apoptosis pathway. Moreo-
ver, it has been shown previously that TNFSF6/CD95L
induces reactive oxygen intermediate formation that, in turn,
activates the src family kinase 'Yes', which rapidly associates
with and phosphorylates EGFR. Activated EGFR triggers
CD95-tyrosine phosphorylation, which is a signal for mem-
brane targeting of the EGFR/CD95 complex, and subse-
quently recruits the Fas-associated death domain and
induces apoptosis [33]. Further, CD95L-induced cell death is
enhanced by EGFR inhibition [34], which is exactly what we
see in our cells, and both the genes encoding these proteins
are identified as Egr1 targets by the present study. Con-
versely, inhibition of expression and/or the transcriptional
activity of Egr1 and Egr3 are known to repress FasL activation
[35], suggesting that Egr1 is essential for FasL expression.
These observations indicate that UV-induced Egr1 expression
may lead to apoptosis through stimulation of the classic TNF/
CD95-initiated pathway of apoptosis and not through the
p53/p73 pathway (Figure S4 in Additional data file 4). Previ-
ous reports from our laboratory have shown that, under nor-
mal growth conditions, Egr1 is required for growth and
proliferation of prostate cancer cells [13,36]. Conversely, in
the present study we observe that when prostate cancer cells
are UV irradiated, Egr1 functions in inducing apoptosis of
these cells. Our group and others have shown earlier that Egr1
can undergo several post-translational modifications, such as
phoshorylation (approximately 25% of Egr1 is made up of
Ser/Thr), acetylation and sumoylation [37]. It has also been
shown previously that the active form of Egr1 protein pro-
duced by UV induction is highly phosphorylated, in contrast
to the Egr1 induced by serum, growth factors, or 12-O-tetra-
decanoylphorbol-13-acetate (TPA). The nature of the phos-
phorylated forms of Egr1 has not yet been analyzed, but
phosphorylated forms bind to DNA more efficiently [37,38].
Therefore, we hypothesize that the differential post-transla-
tional modifications of this protein enable it to function in
several different pathways depending on the stimulus that
induces its expression. Also, our group has previously shown
that p53 is a target of Egr1 and is responsible, in turn, for the
role of Egr1 as a pro-apoptotic protein [38]. For our present
study we used M12 prostate cancer cells, which are SV40 T
antigen transformed and, hence, there is very little unbound
native p53 available in them. Therefore, it was not surprising
that the gene expression of p53 after UV induction did not
show much change. In addition, we also did not see changes
in gene expression for p73 and PTEN transcripts. Therefore,
it seems that the p53/p73/PTEN pathways are not very active
in these cells, consistent with the epigenetic suppression
commonly observed for these genes in prostate cancer,
whereas Egr1 does induce the expression of pro-apoptotic
genes, such as TNFSF6, which are responsible for its apop-
totic response in these cells. Previous studies have shown that
the pro-apoptotic protein 'Bax' undergoes polymerization
and then translocates to the mitochondrial membrane, lead-
ing to mitochondrial membrane depolarization and liberation
of nuclease activity but not cytochrome c [39]. Here, we iden-
tified that the Bax receptor, TOM22, is a target of Egr1, which
is over-expressed in our UV-treated cells. This protein is a
translocase of the outer membrane of mitochondria and acts
as a receptor for BAX Halpha1, which is an important pro-
apoptotic protein [40] that may act to facilitate a Bax-
dependent apoptosis analogous to the mechanism observed
in UV-stimulated keratinocytes. Hence, by over-expression of
TOM22, 'Bax' signaling leads to enhanced apoptosis. Another
target gene, TC21 (RRAS2), is known to mediate transforma-
tion and cell survival via the activation of the Phosphoi-
nositide 3-kinase (PI3K)/AKT and Nuclear factor κB (NFκB)
signaling pathway [41], and this gene is down-regulated in
our data set, which is in accordance with the role of Egr1 in
growth inhibition. Affymetrix gene expression analysis also
identified several other apoptosis related genes in the list of
significantly deregulated genes, such as c-jun,  junD,  fosB,
TNFSF9, and TNFSF13, which might play important roles in
the apoptosis pathway after UV irradiation. In addition,
EGFR, which has a proven role in proliferation of cells, was
also inhibited by Egr1, reinforcing the role of Egr1 in growth
inhibition. Our data clearly show that Egr1 is a mediator of
transcription of numerous pro-apoptotic genes, which may
work concordantly in UV-stimulated prostate cancer cells.
Therefore, all these target genes concordantly function in
leading to Egr1-dependent apoptosis and growth inhibition.
In conclusion, this is the first comprehensive study to identify
approximately 283 targets of Egr1 with the aid of high
throughput ChIP-on-chip analysis. We have shown that,
upon UV stimulation, prostate cancer cells undergo Egr1-
dependent apoptosis and this function of Egr1 is mediated by
at least several of the newly identified target genes.
Conclusion
We have shown that UV irradiation of prostate cancer cells
leads to rapid and extensive induction of Egr1 via activation of
the EGFR/ERK1/2 pathway and to apoptosis. Using ChIP-on-
chip, we observed that the increased Egr1 binds to an exten-
sive profile of over approximately 288 promoters. We con-
firmed that promoter binding corresponds to the regulation
of gene expression for many of these target promoters. The
expression of at least 23 of the target genes are known to be
correlated with activation of EGFR. Moreover, this report
demonstrates that EGFR itself is a target of Egr1 and Egr1
inhibits its expression, suggesting a negative feedback loop inhttp://genomebiology.com/2008/9/11/R166 Genome Biology 2008,     Volume 9, Issue 11, Article R166       Arora et al. R166.11
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order to limit EGFR expression and, hence, its function (Fig-
ure 6). Egr1 also binds to a panel of apoptotic factors, leading
to alteration of their transcript levels, and siRNA experiments
confirm that Egr1 is essential for the induction of these factors
and for apoptosis. We propose that the newly identified tar-
gets might play a role in the EGFR-promoted apoptotic
response and provide an explanation of the role of Egr1 in
UV-irradiated cells.
Materials and methods
Cell culture and treatment
Prostate P69 cells are low-tumorigenic, SV40-Tag trans-
formed human epithelial, prostate cells and M12 cells are a
metastatic cancerous derivative of P69 [23]. The M12 cells
used here were a gift of S Plymate and are insensitive to
androgen. They were cultured as described previously [37].
For UV-C irradiation (40 J/m2) the medium was removed
and collected in separate tubes, cells were then irradiated in a
UV-Stratalinker (Stratagene, la Jolla, CA, USA) and the col-
lected medium was then added back to them. For mock treat-
ment, the growth medium was collected in separate tubes and
then added back after the UV treatment was completed in the
parallel set. Apoptosis in cells treated with UV-C was detected
using anti-PARP antibody from Sigma (P1991-1VL, St. Louis,
MO, USA). Suramin and EGFR inhibitor (PD153035) were
obtained from Calbiochem (San Diego, CA, USA). ERK1/2
inhibitor (U0126) was obtained from Promega (Madison, WI,
USA).
Western blot analysis
Western blot analyses were performed as described [24].
Antibodies against Egr1 (C-19), Egr1 (588), p-Tyr (PY-99; sc-
7020) and EGFR (1005; sc-03) were rabbit polyclonals from
Santa Cruz Biotechnology (Santa Cruz, CA, USA). Phospho
p44/42 MAPK monoclonal antibody was obtained from Cell
Signaling Technology, Inc. (Beverly, MA, USA). Anti-β-actin
antibody was a mouse monoclonal antibody from Sigma. The
images were quantified using image J software from NIH.
Schematic diagram of the activation of Egr1 and the identification of its downstream targets upon UV simulation Figure 6
Schematic diagram of the activation of Egr1 and the identification of its downstream targets upon UV simulation.http://genomebiology.com/2008/9/11/R166 Genome Biology 2008,     Volume 9, Issue 11, Article R166       Arora et al. R166.12
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Cell proliferation assay
A day prior to the experiment, cells were seeded in triplicate
into 6- well plates. At day 0, cells were treated with UV-C and
later harvested for counting, and protein and total mRNA
extraction. This procedure was repeated each day after treat-
ment according to a time course from day 0 to day 6. Cells
were counted using a Beckman Coulter Counter, Z2 (Fuller-
ton, CA, USA). Cell proliferation was also assessed by plating
approximately 1,000 cells in each well of a 96-well plate fol-
lowed by UV-C treatment the next day. From day 2, plates
were analyzed daily using WST1 assay according to the man-
ufacturer's instructions (Roche Diagnostics, Mannheim, Ger-
many). Relative cell numbers were calculated as the change in
proliferation compared to control wells at each time point.
Chromatin immunoprecipitation
M12 prostate cancer cells were used for ChIP as previously
described [24,42]. Briefly, 2 × 107 cells were fixed with for-
maldehyde, neutralized with glycine and rinsed with cold
phosphate-buffered saline. After lysis, samples were soni-
cated to an average DNA length of 1,000 bp (Figure 2). Immu-
noprecipitation of 2 mg pre-cleared chromatin was carried
out by addition of 6 μg of anti-Egr1 (sc-110) antibody and
anti-rabbit IgG antibody (sc-2027, used as a negative con-
trol). Two independent ChIP experiments were performed for
each antibody. The purified ChIP-captured DNA of samples
and the total input DNA consisting of genomic DNA prepared
from control cross-linked cells were amplified using the
Round A/B/C random amplification of DNA protocol [43].
Promoter array hybridization, data analysis, statistics 
and criteria of significance
The promoter arrays with about 12,000 human promoters
spotted in triplicate have been described in our previous
papers as well as in the supplemental Materials and methods
(Additional data file 1) [44,45]. Hybridization and data anal-
ysis were essentially carried out as described in our previous
papers and as described in the supplemental Materials and
methods (Additional data file 1) [24,43]. Significant differen-
tial hybridization between UV and mock-treated control sam-
ples were defined as fold change >1.4 and with p < 0.005.
Functional relationships and potential regulatory relation-
ships among gene products were identified using Pathway
studio 5.0 of Ariadne Inc. (Rockville, MD, USA) and Ingenu-
ity Pathway Analysis of Ingenuity Systems Inc. (Redwood
City, CA, USA). Statistical analyses were essentially as
described in our previous paper [24] and were performed
using the Limma package in BioConductor and the R program
[46]. M-A plots were constructed where:
M = log2 R - log2 G
and
A = (log2 R + log2 G)/2
where R is the intensity of the scanner output signal for the
experimental sample fluorophore (channel 2, Ch2), and G is
the scanner output signal for the reference sample fluoro-
phore (channel 1, Ch1) on the background-subtracted, nor-
malized, and scaled channel intensities. B statistics [46], and
Chi-squared test with Yates criteria were calculated as imple-
mented in the R program. B is equivalent to a 'penalized' t-
statistic:
T = <M>/√[(a + s2)/n]
where 'a' is the penalty estimated from the mean of M-values
(<M>), and standard deviation of the sample variances (s2).
Random genes were chosen from the promoter array for com-
parison with our significantly detected gene list. For this, we
used command 'sample' in the R program to randomly select
200 or 1,000 numbers from 1 to 12,000 without replacement,
where 12,000 is the total number of genes represented on the
array and the corresponding genes are the 1,000 random
genes. Chi square and Fisher exact test were done using the R
program.
Microarray expression analysis
All microarray expression analyses were performed in dupli-
cate using GeneChip® U133 Plus 2 arrays (Affymetrix, Inc.,
Santa Clara, CA, USA) as described [24]. Statistical analysis
was carried out with the aid of the Cyber-t software [47]. The
analysis module computes regularized t-tests using a Baye-
sian estimate of the variance among the gene measurements
to infer significant gene changes; p  < 0.001 genes were
accepted as differentially expressed.
Validation of gene expression by qRT-PCR
qRT-PCR using Sybr Green (Applied Biosystems, Carlsbad,
CA, USA) was performed as described previously to verify
ChIP-Chip microarray analysis as well as to measure the gene
expression changes of the target genes [24,43,46]. To validate
the promoter array results, primers for 25 genes were
designed such that the amplicons have at least one putative
Egr1 binding site identified by the TF SEARCH program TESS
[48]. PCR primers of the genomic regions were designed
using the IDT Primer quest software (IDT technologies, Cor-
alville, IA, USA) (primer sequences can be provided on
request). For gene expression studies, primers were designed
in the exon regions of the genes and the GAPDH gene was
used as an internal control. The relative quantification was
given by the Ct values, determined for triplicate reactions for
test and reference samples for each target and for the internal
control gene (GAPDH). Relative expression level was deter-
mined as 2-ΔΔCt, where ΔΔCt = ΔCt (target sample) - ΔCt (ref-
erence sample).
siRNA and transfection
siRNA against Egr1 was obtained from Dharmacon (Lafay-
ette, CO, USA). Briefly, four pooled siRNA duplexes were
transiently transfected into M12 prostate cancer cells follow-http://genomebiology.com/2008/9/11/R166 Genome Biology 2008,     Volume 9, Issue 11, Article R166       Arora et al. R166.13
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ing the Dharmacon protocol using Dharmafect reagent 1.
Mock transfection was done in parallel using SiGenome con-
trol (Dharmacon) as negative control. The concentration of
siRNA used was standardized to get maximum knockdown
without affecting the viability of the cells. To study the effect
of siRNA on downstream targets of Egr1, cells were treated
with UV (40 J/m2) 48 h after the transfection, and RNA iso-
lation was done 2 h after UV treatment as described.
Abbreviations
ChIP: chromatin immunoprecipitation; EBR: Egr1 binding
site; EGFR: epidermal growth factor receptor; Egr1: Early
growth response-1; PARP: Poly(ADP)-ribose polymerase;
qRT-PCR: quantitative real time PCR; siRNA: small interfer-
ing RNA; UV: ultraviolet.
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